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Abstract 
Parkinson’s disease is characterized by progressive degeneration of 
dopaminergic neurons. Thus the development of therapeutic neuroprotection and 
neurorescue strategies to mitigate disease progression is important. In this study 
we evaluated the neuroprotective/rescue effects of erythropoietin Fc fusion 
protein (EPO-Fc) and carbamylated erythropoietin Fc fusion protein (CEPO-Fc) 
in a rat model of Parkinson’s disease. Adult female Sprague-Dawley rats 
received intraperitoneal injection of EPO-Fc, CEPO-Fc or PBS. Behavioral 
evaluations consisted of rota-rod, cylinder and amphetamine-induced rotation 
tests. In the neuroprotection experiment, the CEPO-Fc group demonstrated 
significant improvement compared with the EPO-Fc group on the amphetamine-
induced rotation test throughout the four-week follow-up period. Histologically, 
significantly more tyrosine hydroxylase (TH)-positive neurons were recognized in 
the substantia nigra (SN) pars compacta in the CEPO-Fc group than in the PBS 
and EPO-Fc groups. In the neurorescue experiment, rats receiving CEPO-Fc 
showed significantly better behavioural scores than those receiving PBS. The 
histological data concerning striatum also showed that the CEPO-Fc group had 
significantly better preservation of TH-positive fibers compared to the PBS and 
EPO-Fc groups. Importantly, there were no increases in hematocrit or 
hemoglobin levels in the CEPO-Fc group in either the neuroprotection or the 
neurorescue experiments. In conclusion, the newly developed CEPO-Fc might 
confer neuroprotective and neurorescue benefits in a rat model of Parkinson’s 
disease without the side effects associated with polycythemia. CEPO-Fc might 
be a therapeutic tool for patients with Parkinson’s disease. 
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1. Introduction  
Parkinson’s Disease (PD) is a neurodegenerative disease of the central nervous 
system (CNS) characterized by dopaminergic loss in the nigrostriatal system. 
The progressive dopaminergic loss leads to symptoms such as resting tremor, 
rigidity, akinesia and disturbances of postural reflex. The currently available 
modes of treatment suppress some of these symptoms but are unable to mitigate 
disease progression (Hornykiewicz et al., 1988; Fearnley et al., 1991; Sethi et al., 
2002). Effectively modeling this neurodegenerative process is an important step 
toward developing neuroprotective and neurorescue therapeutic strategies. 
Erythropoietin (EPO) is a pleiotropic cytokine originally identified for its role 
in erythropoiesis (Sasaki et al., 2003). Recent studies have revealed various 
other effects of EPO, however. Its neuroprotective effects were observed in 
animal models of stroke and traumatic brain injury (Cerami et al., 2001; 
Sakanaka et al., 1998; Wang et al., 2004; Lu et al., 2005; Mahmood et al., 2007). 
EPO has the ability to drive the production of neuronal progenitors from neural 
stem cells (Shingo et al., 2001). In addition, EPO also stimulates progenitor cell 
differentiation into neurons, and it is involved in the maturation of astrocytes and 
oligodendrocytes (Wang et al., 2004; Lee et al., 2004; Sugawa et al., 2002). 
These previous studies have motivated the search for additional roles of EPO, 
and a stroke clinical trial with EPO was recently conducted (Ehrenreich et al., 
2009), yet some adverse effects have led to safety concerns regarding EPO. One 
of the concerns is that sustained high hematocrit causes endothelial damage and 
could increase susceptibility to vascular disease in mouse brains (Ongunshola et 
al., 2006). The fact that EPO increases hematocrit and hemoglobin levels thus 
precludes any possible clinical applications of EPO. Consequently, the 
development of erythropoietin analogues that are predominantly neuroprotective 
and that lack hematopoietic activity should open new therapeutic possibilities in 
the treatment scenario of PD.  
One new pharmaceutical composition that might meet these criteria is a 
fusion protein developed by Polymun Scientific that consists of the Fc domain 
and hinge region of human IgG1 and two recombinant human EPO molecules. 
This construct was chosen because the fusion protein contains the constant 
region of an immunoglobulin and is expected to have a prolonged half-life. This 
final product is called the EPO-Fc fusion protein (EPO-Fc). EPO-Fc is often 
carbamylated as one means of avoiding undesirable side effects. Carbamylation 
of a protein is a chemical modification characterized by non-enzymatic reaction of 
the cyanate ion with the free Epsilon NH2 group of lysines (Bar-or et al., 2011). 
Since this process alters protein conformation, the newly formed carbamylated 
erythropoietin Fc fusion protein (CEPO-Fc) does not bind the classic EPO 
receptor, which explains the absence of erythropoietic activity (Leist et al., 2004). 
Importantly, carbamylated erythropoietin (CEPO) can also cross the blood-brain 
barrier (BBB) in rats and humans, as EPO can (Brines et al., 2000; Ehrenreich et 
al., 2004; Verdonck et al., 2007; Siren et al., 2009; Bouzat et al., 2011). 
Based on this background, we examined whether EPO-Fc and CEPO-Fc 
have neuroprotective and neurorescue effects in a rat model of PD in this study. 
Because PD is a chronic and progressive neurodegenerative process, strategies 
aimed at slowing its development may be important. Considering this, in the 
neuroprotection experiment we evaluated the ability of both EPO-Fc and CEPO-
Fc to mitigate dopaminergic neuronal loss induced by 6-OHDA unilateral right 
striatal lesion. In this experiment, rats received the first dose of the respective 
drug before 6-OHDA administration. In the neurorescue experiment, on the other 
hand, we evaluated if EPO-Fc and CEPO-Fc have potential therapeutic role in a 
rat model of Parkinson’s disease. In this context, rats received the first dose of 
the respective drug two weeks after 6-OHDA lesion and were already diseased 
animals. 
2. Results 
2.1. Study 1: Neuroprotection experiment 
2.1.1. Behavioural tests  
2.1.1.1. Rota-rod test               
On the rota-rod test, measuring the longest time that a rat was able to remain on 
a rota-rod device, both the EPO-Fc and CEPO-Fc groups demonstrated 
improvement throughout the follow-up period after 6-OHDA injection. In contrast, 
the PBS group tended to worsen over time (Fig. 2A). 
2.1.1.2 Cylinder test 
Scores on the cylinder test in the EPO-Fc group were significantly better than 
those in the PBS group at two and four weeks after the 6-OHDA lesion (Fig.2B. 
contralateral bias: 51±7.9%; 33±12.9% for EPO-Fc group; 82±4.8%; 74±7.5% for 
PBS group at two and four weeks after the lesion, respectively. ** p<0.05 CEPO-
Fc, EPO-Fc vs PBS and F=5.17 at two weeks; #p <0.05 EPO-Fc vs PBS and 
F=4.18 at four weeks). 
In the CEPO-Fc group, the scores ameliorated over time and were 
significantly better than those in the PBS group at one, two and three weeks after 
the 6-OHDA lesion (contralateral bias: 56±6.3%; 54±8.9%; 41.5±9.2% for CEPO-
Fc group one, two and three weeks after the lesion, respectively; 81±4.9%; 
82±4.8%; 78±6%, for PBS group. *p<0.05 CEPO-Fc vs PBS at one (F=4.41) and 
three (F=4.58) weeks after the lesion; ** p<0.05 CEPO-Fc, EPO-Fc vs PBS and 
F=5.17 at two weeks after the lesion).  
2.1.1.3. Amphetamine-induced rotation test 
The number of amphetamine-induced rotations decreased significantly at four 
weeks after lesion in the EPO-Fc group (8.5±1.4turns/min) compared to that in 
the PBS group (13.9±1.4turns/min) (Fig. 2C. **p<0.05 EPO-Fc vs PBS ). 
Rats receiving CEPO-Fc had a significantly smaller number of 
amphetamine-induced rotations at both two and four weeks after 6-OHDA 
injection (5.7±0.4; 3.8±0.9, respectively) compared with those receiving PBS 
(9.9±0.1; 13.9±1.4, respectively) (Fig.2C. *p<0.05 CEPO-Fc vs EPO-Fc at two 
and four weeks; ***p<0.01 CEPO-Fc vs PBS at two and four weeks; F=7.89 and 
F=15.48 at two and four weeks, respectively). 
Interestingly, the number of turns/min in the CEPO-Fc group was also 
significantly smaller than that observed in the EPO-Fc group at two and four 
weeks after 6-OHDA administration (9.1±1.3; 8.5±1.4 for EPO-Fc and 5.7±0.4; 
3.8±0.9 for CEPO-Fc, respectively).   
Moreover, in the PBS group, the number of amphetamine-induced rotations 
increased over time and was higher at four weeks than at two weeks after 6-
OHDA administration (13.9±1.4; 9.9±0.1, respectively). Conversely, in both the 
EPO-Fc and CEPO-Fc groups, the number of rotations decreased during the 
follow-up and was smaller at four weeks than at two weeks after 6-OHDA 
injection (8.5±1.4; 9.1±1.3 for EPO-Fc and 3.8±0.9; 5.7±0.4 for CEPO-Fc, 
respectively). This suggests that the PBS group worsened over time, while the 
CEPO-Fc and EPO-Fc groups, in contrast, improved their behavioural function 
during our experiment. It is important to note that the CEPO-Fc group showed 
significantly better scores than the EPO-Fc group at both two and four weeks 
after 6-OHDA administration.   
2.1.2. Hematocrit and Hemoglobin                                                                                              
In the EPO-Fc group, hematocrit and hemoglobin levels raised precipitously, with 
peak values reached eight days after the first injection of EPO-Fc (EPO-Fc 
group: 47.6±1.7% and 51.3±2.5% at four and eight days after first injection of 
EPO-Fc). In contrast, hematocrit and hemoglobin levels in the CEPO-Fc and 
PBS groups showed no such increase, but rather remained stable within normal 
values. Interestingly, increments on both hematocrit and hemoglobin values in 
the EPO-Fc group were significantly greater than those in the CEPO-Fc and the 
PBS groups (Fig. 3A for hematocrit. *p<0.01 EPO-Fc vs PBS, CEPO-Fc and 
F=12.81 at four days after i.p.injection; **p<0.0001 EPO-Fc vs PBS, CEPO-Fc 
and F=18.07 at eight days after i.p. injection) (Fig. 3B for hemoglobin. *p<0.01 
EPO-Fc vs PBS, CEPO-Fc. F=12.92 at four days after i.p. injection; **p<0.0001 
EPO-Fc vs PBS, CEPO-Fc and F=18.14 at eight days after i.p. injection).  
2.2.3. Immunohistochemistry 
In the PBS group, severe destruction of tyrosine hydroxylase (TH) fibers (Fig. 4B) 
was observed. On the other hand, there was profound and significant 
preservation of TH-positive fibers in the EPO-Fc and the CEPO-Fc groups (Fig. 
4C and D). Moreover, the preservation of TH-positive fibers in the EPO-Fc and 
the CEPO-Fc groups was also significantly greater than that observed in the PBS 
group (Fig. 4E.EPO-Fc group: 65±4% relative to intact side; CEPO-Fc group: 
71±2% relative to intact side; PBS group: 32±1% relative to intact side. 
***p<0.0001 EPO-Fc vs PBS; ****p<0.0001 CEPO-Fc vs PBS and F=76.74).  
Similarly, significant preservation of dopaminergic TH-positive neurons was seen 
in the Substantia Nigra (SN) pars compacta and ventral tegmental area (VTA) in 
both the EPO-Fc (Fig. 5C) and the CEPO-Fc (Fig. 5D) groups compared to the 
PBS group (Fig. 5B.) (Fig.5E for SN: EPO-Fc group: 62±4% relative to intact 
side; CEPO-Fc group: 71±2% relative to intact side; PBS group: 46±6% relative 
to intact side. *p<0.05 EPO-Fc vs PBS; **p<0.05 CEPO-Fc vs EPO-Fc; 
***p<0.0001 CEPO-Fc vs PBS and F=14.11) (Fig.5F for VTA. EPO-Fc group: 
68±3% relative to intact side; CEPO-Fc group: 81±2% relative to intact side; PBS 
group: 31±2% relative to intact side.*p<0.0001EPO-Fc vs PBS; **p<0.01 CEPO-
Fc vs EPO-Fc; ***p<0.0001CEPO-Fc vs PBS and F=97.01). Furthermore, there 
was more profound and significant preservation in the CEPO-Fc group even 
compared to the EPO-Fc group.  
2.2. Study 2: Neurorescue experiment 
2.2.1. Behavioural tests 
2.2.1.1. Rota-rod test 
Animals in the CEPO-Fc group earned significantly better scores on the rota-rod 
test than those in the PBS group did at two and three weeks after intraperitoneal 
administration of CEPO-Fc (CEPO-Fc group: 77±2.2%, 89±5.2% at two and 
three weeks after CEPO-Fc injection, respectively; PBS group: 53±1.5%, 
52±5.3% at two, and three weeks after PBS injection, respectively) (Fig. 
6A.*p<0.05 CEPO-Fc vs PBS and F=3.98 at two weeks; **p<0.01 CEPO-Fc vs 
PBS and F=9.95 at three weeks). It is worth noting that the beneficial effect in the 
CEPO-Fc group continued for at least three weeks after CEPO-Fc administration. 
2.2.1.2. Cylinder test 
After the CEPO-Fc injection, the scores for forelimb asymmetry in the CEPO-Fc 
group improved continually throughout the follow-up period (Fig.6B). The scores 
in the CEPO-Fc group continued to improve for at least four weeks after CEPO-
Fc administration. Most importantly, the CEPO-Fc group earned its best scores at 
four weeks after administration of CEPO-Fc, with a statistically significant 
difference from the EPO-Fc group (24±6%, 46±9% for CEPO-Fc and EPO-Fc, 
respectively). We speculate that these progressive and persistent improvements 
in the scores of the CEPO-Fc group indicate a more prolonged beneficial effect of 
CEPO-Fc (*p<0.05 CEPO-Fc vs EPO-Fc and F=5.38 at four weeks after i.p. 
injection).                                                                                                               
2.2.1.3. Amphetamine-induced rotation test 
 The number of amphetamine-induced rotations in the CEPO-Fc and EPO-Fc 
groups decreased significantly at two weeks after the intraperitoneal 
administration of the respective drug (4.7±1.3; 4.1±1.2 and 8.1±2.6 turns/min for 
CEPO-Fc, EPO-Fc and PBS, respectively (Fig. 6C. *p<0.01 CEPO-Fc, EPO-Fc 
vs PBS and F=7.27). 
This improvement persisted at least four weeks after CEPO-Fc administration: 
the number of amphetamine-induced rotations at four weeks was smaller than 
that observed at two weeks after the intraperitoneal injection (3.3±1.5 and 
4.7±1.3turns/min, respectively). The beneficial effect of CEPO-Fc was observed 
even at four weeks after CEPO-Fc injection, although it was not statistically 
significant. 
2.2.2. Hematocrit and Hemoglobin 
In the neurorescue experiment, the levels of hematocrit and hemoglobin 
remained stable within normal values in both the CEPO-Fc and the PBS groups. 
In the EPO-Fc group, in contrast, these values were significantly higher, and the 
peak level occurred seven days after EPO-Fc injection (Fig. 3C and Fig 3D. 
hematocrit: 49±1.7%; hemoglobin: 16.9±0.5g/dl, respectively). 
Moreover, in the EPO-Fc group, hematocrit and hemoglobin levels did not 
return to normal levels within twenty-eight days after EPO-Fc injection 
(hematocrit: 43.4±2%; haemoglobin: 14.7±0.75g/dl, respectively). These levels 
were significantly higher than those in the CEPO-Fc and the PBS groups (Fig. 3C 
for hematocrit. **p<0.0001 EPO-Fc vs PBS, CEPO-Fc and F=26.95 at seven 
days after i.p. injection; *p<0.05 EPO-Fc vs PBS, CEPO-Fc and F=8.64 at 
twenty-eight days after i.p. injection) (Fig. 3D **p<0.0001 EPO-Fc vs PBS, 
CEPO-Fc. F=29.09 at seven days after i.p. injection;*p<0.05 EPO-Fc vs PBS, 
CEPO-Fc and F=8.48 at twenty-eight days after i.p. injection). 
2.2.3. Immunohistochemistry 
In the neurorescue experiment, analysis of the striatum revealed significant 
preservation of TH-positive fibers both in the EPO-Fc (Fig. 7C) and the CEPO-Fc 
(Fig. 7D) groups compared with the PBS group (Fig. 7B). Moreover, TH-positive 
fibers in the CEPO-Fc group were significantly better preserved than those in the 
EPO-Fc group (Fig. 7E: EPO-Fc group: 47±4% relative to intact side; CEPO-Fc 
group: 59±5% relative to intact side; PBS group: 20±2% relative to intact side. 
*p<0.05 EPO-Fc vs PBS, **p<0.01 CEPO-Fc vs EPO-Fc, ***p<0.0001 CEPO-Fc 
vs PBS and F=97.01). 
In relation to these findings, there was also significant preservation of 
dopaminergic TH-positive neurons in the SN pars compacta in both the EPO-Fc 
and the CEPO-Fc groups (Fig. 8C and D). Importantly, the number of preserved 
dopaminergic TH-positive neurons in the EPO-Fc and the CEPO-Fc groups was 
significantly greater than that in the PBS group (Fig. 8E for SN: EPO-Fc group: 
64±3% relative to intact side; CEPO-Fc group: 67±3% relative to intact side; PBS 
group: 45±2% relative to intact side. *p<0.05 EPO-Fc vs PBS, **p<0.05 CEPO-Fc 
vs PBS and F=7.84) (Fig.8F for VTA: *p<0.01 EPO-Fc vs PBS; 
**P<0.0001CEPO-Fc vs PBS. EPO-Fc group: 71±3% relative to intact side; 
CEPO-Fc group: 81±2% relative to intact side; PBS group: 35±2% relative to 
intact side and F=95.99). 
3. Discussion 
Because Parkinson’s disease is a chronic and progressive neurodegenerative 
process, strategies aimed at slowing its development may be important. As a 
step toward such strategies, in this study we explored the neuroprotective and 
neurorescue effects of EPO-Fc and CEPO-Fc. Neuroprotection is preventive 
pretreatment before disease onset, while neurorescue is corrective treatment 
after onset (Yasuhara et al., 2006a). 
First the proteins were tested for neuroprotective capacity. Animals in the 
CEPO-Fc group demonstrated statistically significant improvement compared 
with those in the EPO-Fc group on an amphetamine-induced rotation test 
throughout the follow-up period. These results are supported by the observation 
that more TH-positive fibers were preserved in the CEPO-Fc group than in the 
PBS group. In addition, TH-positive neurons in the SN pars compacta were better 
preserved in the CEPO-Fc group than in the PBS or the EPO-Fc group.  
Next the proteins were tested for neurorescue capacity. Animals in the 
CEPO-Fc group showed significantly better behavioural scores than those in the 
PBS group. TH-positive neurons in the SN pars compacta were better preserved 
in the CEPO-Fc group than in the PBS group. The histological data concerning 
the striatum also showed that TH-positive fibers were significantly better 
preserved in the CEPO-Fc group than in the PBS or EPO-Fc group.  
The protective effects of EPO are mediated through a receptor complex 
consisting of the EPO-R and the common beta receptor (Brines et al., 2004, 
2005). The hematopoietic effects, on the other hand, are due to EPO binding to 
the (EPO-R/EPO-R) receptor, a dimer composed of two EPO receptor units. 
Because the affinity of EPO to the tissue-protecting receptor is substantially lower 
than its affinity to (EPO-R/EPO-R), higher EPO concentrations are necessary to 
induce its tissue-protective effects in the central nervous system (CNS) (Cerami 
et al., 2010). Accordingly, some have reported a bell-shaped concentration 
response curve for the beneficial properties of EPO: although high levels are 
most conducive to neuroprotection and neurorescue, they can induce generation 
of reactive oxygen species (ROS), causing a loss of beneficial effects and even 
toxicity (Ehrenreich et al., 2006; Wu et al., 2010; Diaz et al., 2005; Erbayraktar et 
al., 2006). This is one of the limitations of the use of EPO in clinical settings. 
During the neurorescue experiment in the EPO-Fc group, haemoglobin 
and hematocrit levels did not return to normal levels within four weeks after EPO-
Fc injection. The haemoglobin and hematocrit values were also significantly 
higher in the EPO-Fc group than in the CEPO-Fc and PBS groups. These 
parkinsonian rats were exposed to persistent erythrocytosis induced by EPO-Fc. 
This increase in hematocrit and haemoglobin levels precludes any clinical 
application of EPO. The main risks of erythrocytosis include heart failure, 
myocardial infarction, seizures, peripheral thromboembolic events and pulmonary 
embolism (Piloto et al., 2009). These undesirable and life-threatening 
complications are of concern, especially among PD patients, who already have 
one chronic and neurodegenerative process. 
In the CEPO-Fc group, on the other hand, we observed no increase in 
haemoglobin or hematocrit, even using the same multiple injection paradigm 
used in the EPO-Fc group. That is why the greatest advantage of the 
carbamylation of erythropoietin is the elimination of its erythropoietic activity while 
its neuroprotection and neurorescue properties remain intact (Hasselblat et al., 
2006; Kennedy et al., 2005). 
3.1. Advantages of Carbamylated Erythropoieitin Fc Fusion Protein (CEPO-
Fc). 
EPO is a hormone that is neuroprotective in models of neurodegenerative 
diseases (Zhang et al., 2006). In the CNS, however, therapeutic dosages of EPO 
are so high that they affect haematological parameters such as hematocrit and 
haemoglobin (Kikerby et al., 2008; Martin et al., 1991; Bath et al., 2004; 
Greisenegger et al., 2004).  
In addition, EPO has a relatively short serum half life, and the design of a 
fusion protein like EPO but with a longer serum half life is an important medical 
goal (Schriebl et al., 2006). In order to enhance serum half life and improve 
EPO’s pharmacokinetics, the fusion of EPO to the Fc region of an antibody is a 
promising step (Capon et al., 1989). Indeed, the in-vivo serum half life of EPO-Fc 
fusion protein is greater than that of naturally occurring EPO. Moreover, in order 
to promote the full neuroprotective and neurorescue effects of EPO-Fc without its 
side effects related to erythrocytosis, EPO-Fc fusion protein was also 
carbamylated. 
Unlike EPO, CEPO does not bind the classical homodimeric receptor 
EPO-R. Its neuroprotective action appears to require the common beta receptor, 
which explains the absence of erythrocytosis as well as its retention of tissue-
protective properties. 
Recent studies have revealed that CEPO is even more favourable than 
previously thought, given its absence of erythropoietic activity (Nijboer et al., 
2010). CEPO increases renal blood flow, promotes sodium excretion and 
reduces injury-induced increases in procoagulant activity and does not affect 
platelet production (Coleman et al., 2006). Furthermore, treatment with CEPO 
proved to be more effective than EPO in the reduction of inflammatory 
parameters in a brain death model (Nijboer et al., 2010). 
Through chemical modification, such as the carbamylation of at least one 
primary amino group of the lysines and/or the N-terminal amino acid of EPO, the 
hematopoietic effect of this cytokine is considerably reduced while its neuronal 
protective effect remains substantially unaltered. This final product is the newly 
developed CEPO-Fc, consisting of two molecules of CEPO fused to the Fc part 
of IgG1 (Schreibl et al., 2006). 
Thus the selective stimulation of neuroprotective pathways by CEPO, 
which does not act on bone marrow, and the addition of a Fc fusion protein 
property, which increases half life, leads to CEPO-Fc. In the CEPO-Fc group in 
our study, there were no increases in hematocrit and haemoglobin levels, though 
the neuroprotective and neurorescue effects of EPO were maintained. Taken 
together, therefore, our data suggest that CEPO-Fc represents a new opportunity 
to exploit the full potential of EPO without unwanted side effects derived from 
polycythemia and with increased serum half life. 
3.2. Mechanisms for neuroprotection/neurorescue 
The mechanism underlying the neuroprotective/neurorescue effects of EPO and 
its analogue CEPO can be explored through findings of various kinds. Previous 
studies have suggested that EPO and CEPO reduce neuronal apoptosis (Zhou et 
al., 2011; Wei et al., 2006). In addition, there is an endogenous erythropoietin 
system in the brain, which may also protect neurons against oxidative stress. 
Ferrucci et al. (2007) observed a higher prevalence of PD in humans with low 
levels of EPO. Taken together, these anti-apoptotic and anti-oxidative effects 
may ameliorate the oxidative stress caused by the 6-OHDA neurotoxin in the 
nigro-striatal tract (Aluf et al., 2006). 
 In addition to exerting an anti-apoptotic effect, CEPO may induce Sonic 
hedgehog (SHH), a mitogen known to enhance neurogenesis and 
neuroprotection (Amankulor et al., 2009; Wu et al., 2010; Wang et al., 2007). It is 
possible that SHH is also related to neurotrophins, since BDNF up-regulation was 
mutually linked to elevated levels of SHH (Hashimoto et al., 2008). In fact, SHH is 
responsible for mediating CEPO’s effects on the proliferation and differentiation 
of neural progenitor cells, which explains its beneficial effects in the CNS (Ahn et 
al., 2005; Amankulor et al., 2009; Wu et al., 2010; Wang et al., 2007). 
 Bouzat et al. (2011) demonstrated that CEPO blocked the early 
development of cerebral edema by decreasing ERK-1/-2 phosphorylation. This 
decrease in phosphorylation is probably mediated by the CEPO-induced up-
regulation of SHH (Bar-Or et al., 2011).  
 Besides its important effects on the SHH pathway, CEPO might exert its 
beneficial effects on nerve cells through its action on MHC-I (major 
histocompatibility complex type I) molecules. MHC-I molecules are involved in 
nerve plasticity and play an important role in nerve cell recovery by increasing 
outgrowth of axons in injured neurons (Oliveira et al., 2004; Fu et al., 2010; Huh 
et al., 2000). In this context, the immunomodulatory effects of CEPO induce 
stable improvement in neurite outgrowth, which is crucial in restoring the CNS 
after injury (Fu et al., 2010; Adembri et al., 2008; Schmidt et al., 2008). Thus 
CEPO not only has neuroprotective effects but also acts on immunomodulation. 
 In relation to its anti-inflammatory properties, CEPO attenuated the 
expression of inflammatory cytokines (Beck et al., 1986; Hirano et al., 1992). 
CEPO is also related to reduced expression of p-selectin. Increased levels of p-
selectin have been observed in acute stroke patients and are associated with 
various pro-thrombotic conditions. Furthermore, CEPO was also associated with 
lower levels of TNF in a model of infectious peritonitis, possibly by decreasing 
apoptosis and inflammation while improving the rate of healing and regeneration 
of tissue after damage (Erbayraktar et al., 2009; Cerami et al., 2010). 
 Consequently, CEPO not only acts as an anti-inflammatory pathway, but 
also elicits several other cytoprotective properties without causing the side effects 
associated with increased levels of hematocrit and haemoglobin.  
4. Conclusion 
We showed that CEPO-Fc, a newly developed carbamylated erythropoietin, may 
exert neuroprotective and neurorescue effects in a rat model of Parkinson’s 
disease without the side effects associated with polycythemia. Consequently, this 
newly developed carbamylated erythropoietin Fc fusion protein is a potential 
therapeutic strategy for Parkinson’s disease. 
5. Experimental Procedures 
5.1. Materials 
In this study we evaluated the neuroprotective and neurorescue capacities of 
EPO-Fc and CEPO-Fc. EPO-Fc is an engineered erythropoietin fusion protein 
consisting of two human recombinant EPO molecules fused to the Fc domain of 
a human IgG1 antibody. Its hematopoietic effects are mediated by the binding of 
EPO to the (EPO-R/EPO-R) receptor, a dimer composed of two EPO receptor 
units. Its tissue-protective properties, on the other hand, are mediated by its 
binding to a heteroreceptor complex consisting of an EPO receptor monomer and 
the common beta receptor (Brines et al., 2004). 
           Since carbamylation of EPO prevents its binding to the (EPO-R/EPO-R) 
receptor, the hematopoietic activity of EPO-Fc is eliminated by carbamylation. 
           Considering that PD is a progressive and chronic neurodegenerative 
disease, CEPO-Fc may represent a promising alternative when long-term 
treatment is necessary and hematopoiesis is an unwanted side effect. 
            Based on previously published studies using EPO and CEPO (Liu et 
al.,2011; Leconte et al., 2011; Zhou et al., 2011), we performed preliminary 
experiments with 0.04, 0.4 and 4.0 mg/kg of body weight (BW). Finally we 
determined 0.4mg/kg per BW as the best dosage for i.p administration. EPO-Fc 
and CEPO-Fc used in experiments were diluted with PBS, accordingly to 
previous reports (Sturm et al., 2010). Consequently, we used PBS in control 
group.              
5.2. Subjects 
Our study is composed of two parts: neuroprotection experiments and 
neurorescue experiments. In the neuroprotection experiments, we evaluated the 
neuroprotective role of CEPO-Fc and EPO-Fc. Rats received their respective 
drug three times: one day before the 6-OHDA lesion (day -1), on the day of 6-
OHDA lesion (day 0) and one day after the lesion (day 1) (Fig. 1A). 
In order to evaluate the potential clinical application of EPO-Fc and CEPO-
Fc, we also performed neurorescue experiments. In this context, the drugs were 
administered two weeks after the 6-OHDA lesion, to evaluate their potential in 
already diseased animals (Fig. 1B). 
Adult female Sprague-Dawley rats (Charles River, Kanagawa, Japan) 
(n=36 for neuroprotection experiments, n=36 for neurorescue experiments and 
n=8 for non-lesioned control) weighing 200-250g at the beginning of the 
experiments were used according to the approved guidelines of the Institutional 
Animal Care and Use Committee of Okayama University. They were housed two 
per cage in a temperature- and humidity-controlled room which was maintained 
on a 12-hour light/dark cycle with free access to food and water. 
5.3. Experimental design 
5.3.1. Study 1: neuroprotection 
Rats (n=36) were divided into three groups: EPO-Fc (n=12), CEPO-Fc (n=13), 
PBS (n=11).Rats received their respective drug (0.4mg/kg per BW) or PBS 
intraperitoneally for three days. The first injection of the drug was administered 
one day prior to 6-OHDA injection. The second injection was administered 
immediately before the 6-OHDA lesion and the third injection one day after the 6-
OHDA lesion. 
Behavioural tests consisted of amphetamine-induced rotation, rota-rod 
and cylinder tests. All animals were evaluated weekly with the rota-rod and 
cylinder tests. Amphetamine-induced rotation tests were performed two and four 
weeks after the 6-OHDA lesion.  
In order to evaluate hematocrit and haemoglobin parameters, blood 
samples were collected one day before administration of EPO-Fc, CEPO-Fc or 
PBS for control and at three days, one week and four weeks after the 6-OHDA 
lesion. 
All rats were followed for four weeks after the 6-OHDA lesion and were 
then euthanized for histological analysis (Fig. 1A).  
5.3.2. Study 2: neurorescue 
Rats (n=36) were divided into three groups named EPO-Fc (n=12), CEPO-Fc 
(n=12) and PBS (n=12). Rats received their respective drug (0.4mg/kg per BW) 
or PBS intraperitoneally for three days. 
Behavioural tests consisted of amphetamine-induced rotation, rota-rod 
and cylinder tests. All animals were evaluated weekly with the rota-rod and 
cylinder tests. Amphetamine-induced rotation tests were performed two, four and 
six weeks after 6-OHDA lesion.  
The first dose of EPO-Fc, CEPO-Fc or PBS was administered 
intraperitoneally exactly 14 days after the 6-OHDA lesion and after the 
behavioural tests had confirmed that all animals were indeed Parkinson’s disease 
models. The second and third doses were administrated 15 and 16 days after the 
6-OHDA lesion, respectively.  
For measurements of hematocrit and haemoglobin parameters, blood 
samples were collected on days 13, 17 and 21 after the 6-OHDA lesion. 
All rats were followed for six weeks and were then euthanized for 
histological analyses (Fig. 1B). 
5.4. Surgical Procedures 
All rats were anesthetized with sodium pentobarbital (35mg/kg, i.p.) and placed in 
a stereotaxic apparatus (Narishige, Tokyo, Japan). A midline skin incision was 
made and a hole was then drilled in the skull. After this procedure, 6-OHDA 
(20μg, concentration: 5μg/μl, dissolved in 0.9% saline containing 0.2mg/ml 
ascorbic acid; Sigma-Aldrich, St. Louis, MO, USA) was injected into the right 
striatum with a 28-gauge Hamilton Syringe (1.0mm anterior, 3.0mm lateral to the 
bregma, and 5.0mm ventral to the surface of the brain with the tooth-bar set at -
3.0mm) (Paxinos and Watson, 1998). The injection rate was 1μl/min. After the 
injection, the syringe was left in for an additional 5 minutes before being retracted 
slowly (1mm/min).  
5.5. Behavioral testing 
Behavioral analysis consisted of the amphetamine-induced rotation test, the rota-
rod test and the cylinder test. Each of these tests was performed at several time 
points (Fig. 1A and Fig. 1B).  
5.5.1. Rota-rod Test 
The rota-rod test was performed to evaluate the degree of akinesia and 
coordination of movements. Before 6-OHDA injection, all rats were pre-trained to 
stay on an accelerating rota-rod (Shinano Seisakusho, Tokyo, Japan) at a 
constant speed of 8rpm until they could remain on the rota-rod for 100sec. After 
three consecutive days of pre-training, we performed three trials, in which the 
rotational speed was gradually increased from 4 to 40rpm within 5min. The 
longest time that the rats remained on the rota-rod was recorded as the baseline. 
Thereafter, the data were presented as percentages of the longest time on the 
rota-rod of three trials relative to the baseline (Takahashi et al., 2008). 
5.5.2. Cylinder Test 
The cylinder test was used to assess the degree of forepaw asymmetry. Rats 
were placed in a transparent cylinder (diameter: 20cm, height: 30cm) for three 
minutes and the number of forepaw contacts to the cylinder wall were counted 
(Schallert et al., 2001). 
5.5.3. Amphetamine-induced rotation Test 
All rats received an injection of amphetamine (2.5 mg/kg, i.p., Dainippon 
Sumitomo Pharma, Osaka, Japan). Rotational behaviours were assessed for 
90min with a video camera. The number of complete 360o body turns in the 
direction ipsilateral to the lesion was counted. The number of turns per minute 
was used for statistical analysis. 
5.6. Blood sampling 
Blood sampling was performed to evaluate both hematocrit and hemoglobin at 
several time points (Fig. 1A and Fig. 1B). 
5.7. Fixation and Sectioning  
Rats were deeply anesthetized with sodium pentobarbital (100mg/kg), perfused 
from the ascending aorta with 200ml of cold PBS followed by 200ml of 4% 
paraformaldehyde (PFA) in PBS. Brains were removed and post-fixed first in the 
same fixative for two days and then in 30% sucrose in phosphate buffer (PB) until 
completely submerged. Six series of coronal sections were cut at a thickness of 
40μm with a freezing microtome and stored at -20oC. 
5.8. Immunohistochemistry 
Free-floating sections for tyrosine hydroxylase (TH) immunohistochemistry were 
blocked with 3% hydrogen peroxide in 70% methanol for 7min. Sections were 
washed three times for 5min each time in PBS. Sections were then incubated 
overnight at 4oC with rabbit anti-TH antibody (1:500; Chemicon, Temecula, CA, 
USA) with 10% normal horse serum. After several rinses in PBS, sections were 
incubated for 1h in biotinylated donkey anti-rabbit IgG (1:500; Jackson Immuno-
Research Lab, West Grove, PA, USA), then for 30min in avidin-biotin-peroxidase 
complex (Vector Laboratories, Burlingame, CA, USA). Subsequently, the 
sections were treated with 3,4-diaminobenzidine (DAB; Vector) and hydroxygen 
peroxide, mounted on albumin-coated slides and embedded with cover glass. 
5.9. Morphological analyses 
The density of TH-positive fibers in the striata of animals was analyzed as 
described previously (Kadota et al., 2009). Five sections at 0.5 ± 1.0mm anterior 
to the bregma were selected for quantitative analysis (Paxinos and Watson, 
1998). The two areas adjacent to the needle track on the lesioned side and the 
two symmetrical areas on the contralateral side were analyzed. The proportion of 
lesions on the intact side was evaluated in each section and the average was 
used for statistical analyses. The images were computer-processed into binary 
images using an appropriate threshold (Scion Image, Scion Corp., Frederick, MD, 
USA). The areas were then calculated and used for statistical analyses. 
Accordingly to our previous publications (Yuan et al., 2008; Kikuchi et al., 2011), 
for counting the number of TH-positive neurons, every fifth 40μm-thick coronal 
tissue section through the substantia nigra pars compacta (SNc) was explored 
using 3 coronal sections respectively at 4.8 and 5.3 mm posterior to the bregma. 
A cell was considered when intact, round and with clear nucleus. The number of 
TH-positive cell bodies in the SNc was counted and the average was used for the 
statistical analysis. 
5.10. Statistical analyses 
All data are shown as average ± standard error. The data were evaluated 
statistically using analysis of variance one way (ANOVA) and subsequent post 
hoc Bonferroni for behavioral tests or Mann-Whitney’s U test for 
immunohistochemical investigations. Statistical significance was preset at p<0.05. 
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Figure Legends 
Fig. 1. Experimental design. 
(A) Neuroprotection experiment: In this experiment 6-OHDA was injected into the 
 striatum on day 0 (encircled by ellipse). Blood samples (dotted arrows) were 
collected one day prior to administration of drugs and at four days, eight days 
and twenty-nine days after the first i.p. administration. Behavioral tests (arrow 
heads) were performed weekly, with the exception of amphetamine-induced 
rotation, which was performed on days 14 and 28. After behavioral evaluation, all 
rats were euthanized (grey triangle) for immunohistochemical analysis.         
(B) Neurorescue experiment: The striatum was lesioned with 6-OHDA on 
 day 0 (encircled by ellipse). Blood samples (dotted arrows) were collected one 
day prior to administration of drugs and at three, seven and twenty-eight days 
after the first i.p. administration. Behavioral tests (arrow heads) were performed 
weekly, with the exception of amphetamine-induced rotation, which was 
performed on days 14, 28 and 42. After behavioral evaluation, all rats were 
euthanized (grey triangle) for immunohistochemical analysis. 
 
Fig. 2. Behavioral tests in the neuroprotection experiment 
(A) Rota-rod test. Dashed lines represent non-lesioned control group. 
EPO-Fc and CEPO-Fc groups demonstrated improvement throughout the 
follow-up period, as shown by the maximum times achieved on the rota-rod 
device. *p<0.05 CEPO-Fc, EPO-Fc, PBS vs non-lesioned control at one week 
after 6-OHDA lesion with F=4.44. **p<0.05 PBS vs non-lesioned control at  
four weeks after 6-OHDA lesion with F=3.61. ***p<0.01 PBS vs non-lesioned 
control at three weeks after 6-OHDA lesion with F=5.11. 
(B) Cylinder test. The contralateral bias of rats in the CEPO-Fc group was  
significantly reduced at one, two, and three weeks after 6-OHDA lesion. In the 
EPO-Fc group, contralateral bias were significantly better than PBS at two and 
four weeks after 6-OHDA lesion.*p<0.05 CEPO-Fc vs PBS with F=4.41 and 
F=4.58 for one and three weeks after 6-OHDA lesion, respectively. **p<0.05 
CEPO-Fc, EPO-Fc vs PBS with F=5.17 at two weeks after 6-OHDA lesion. 
#p<0.05 EPO-Fc vs PBS with F=4.18 at four weeks after 6-OHDA lesion.   
(C) Amphetamine-induced rotation test. The number of amphetamine-induced  
rotations of rats in the EPO-Fc group was significantly reduced compared with 
that in the PBS group at four weeks after 6-OHDA lesion. **p<0.05 EPO-Fc vs 
PBS. In the CEPO-Fc group, a similar reduction was observed compared to the 
PBS group and the EPO-Fc group at both two and four weeks after 6-OHDA 
lesion. ***p<0.01 CEPO-Fc vs PBS and * p<0.05 CEPO-Fc vs EPO. Both EPO-
Fc and CEPO-Fc rats improved over time; PBS rats, in contrast, worsened during 
follow-up. F=7.89 and F=15.48 at two and four weeks after 6-OHDA lesion, 
respectively. 
 
Fig3. Hematocrit and hemoglobin measurements 
(A) Hematocrit in neuroprotection experiment. 
*p<0.01 EPO-Fc vs PBS, CEPO-Fc and F=12.81 at four days after i.p. injection; 
**p<0.0001 EPO-Fc vs PBS, CEPO-Fc and F=18.07 at eight days after i.p. 
injection.         
 (B) Hemoglobin in neuroprotection experiment. 
*p<0.01 EPO-Fc vs PBS, CEPO- Fc and F=12.92 at four days after i.p. injection; 
**p<0.0001 EPO-Fc vs PBS, CEPO- Fc and F=18.14 at eight days after i.p. 
injection. In this experiment, rats received the first dose of the respective drug 
before 6-OHDA striatal lesion. In the EPO-Fc group, levels increased 
precipitously just four days after i.p. injection and peaked eight days after the i.p 
administration. In the CEPO-Fc and PBS groups, in contrast, measurements of 
both hematocrit and hemoglobin remained stable and within normal values.       
(C) Hematocrit in neurorescue experiment.  
**p<0.0001 EPO-Fc vs PBS, CEPO- Fc and F=26.95 at seven days after i.p. 
injection; *p<0.05 EPO-Fc vs PBS, CEPO-Fc and F=8.64 at twenty-eight days 
after i.p. injection.    
(D) Hemoglobin in neurorescue experiment. 
 **p<0.0001 EPO-Fc vs PBS, CEPO-Fc and F=29.09 at seven days after i.p. 
injection; *p<0.05 EPO-Fc vs PBS, CEPO-Fc and F=8.48 at twenty-eight days 
after i.p. injection. In this experiment, rats received the first dose of the respective 
drug two weeks after 6-OHDA striatal lesion and were already diseased rats. In 
the EPO-Fc group, levels increased and peaked seven days after i.p. 
administration. In the EPO-Fc group, levels remained high and did not return to 
normal, even after twenty-eight days after i.p. injection. In the CEPO-Fc and PBS 
groups, in contrast, measurements of both hematocrit and hemoglobin remained 
stable and within normal values. 
 
Fig. 4. Tyrosine hydroxylase immunostaining (TH) in the striatum.   
(A) Strong immunoreactivity in intact striatum. 
(B) Severe destruction of TH-positive fibers in the PBS group.  
(C) Some preservation of TH-positive fibers in the EPO-Fc group. 
(D) Immunoreactivity is more clearly preserved in the CEPO-Fc group. 
(E) Graphic. The EPO-Fc and CEPO-Fc groups demonstrated significantly better 
preservation than the PBS group. ***p<0.0001 EPO-Fc  vs PBS; ****p<0.0001 
CEPO-Fc vs PBS and F=76.74. 
 
Fig. 5. Tyrosine hydroxylase immunostaining (TH) in the substantia nigra (SN) 
and VTA (ventral tegmental area).    
(A) TH-positive cells on SN and VTA on intact side. 
(B) Almost complete absence of TH-positive cells in the PBS group. 
(C) Immunoreactivity is preserved in the EPO-Fc group.    
(D) Better preservation of TH-positive cells in the CEPO-Fc group.  
(E) Graphic. Substantia Nigra. *p<0.05 EPO-Fc vs PBS; **p<0.05 CEPO-Fc vs 
EPO-Fc; ***p<0.0001 CEPO-Fc vs PBS and F=14.11 
(F) Graphic. Ventral Tegmental Area. *p<0.0001 EPO-Fc vs PBS; **p<0.01 
CEPO-Fc vs EPO-Fc; ***p<0.0001 CEPO-Fc vs PBS and F=97.01. 
TH-positive cells were significantly better preserved in the EPO-Fc and CEPO-Fc 
groups than in the PBS group. Moreover, there was more significant preservation 
in the CEPO-Fc group than in the EPO-Fc group. 
 
Fig. 6. Behavioral tests in the neurorescue experiment 
(A) Rota-rod test. Dashed lines represent non-lesioned control group. 
The CEPO-Fc group preformed significantly better than the PBS group did at two 
and three weeks after i.p. administration of CEPO-Fc. *p<0.05 CEPO-Fc vs PBS 
and F=3.98 at two weeks after i.p. injection; **p<0.01 CEPO-Fc vs PBS and 
F=9.95 at three weeks after i.p. injection. #p<0.05  CEPO-Fc, EPO-Fc, PBS vs 
non-lesioned control at two weeks after striatal lesion( F=7.17) and one week 
after i.p injection of the respective drug (F=12.43). ##p<0.01 PBS vs non-
lesioned control at one week after striatal lesion (F=4.05) and at two weeks after 
i.p. injection of the respective drug (F=5.24). ###p<0.01 EPO-Fc, PBS vs non-
lesioned control at three(F=10.16) and four(F=21.57) weeks after i.p. injection of 
the respective drug. 
(B) Cylinder test. In the CEPO-Fc group, contralateral bias decreased just one 
week after i.p. administration of CEPO-Fc. The CEPO-Fc group also perfor- 
med better than the EPO-Fc and PBS groups did and were statistically 
significant at four weeks after i.p. injection of CEPO-Fc when compared to 
EPO-Fc. *p<0.05 CEPO-Fc vs EPO-Fc with F=5.38. 
(C) Amphetamine-induced rotation test. In both the EPO-Fc and the CEPO-Fc 
group, the number of amphetamine-induced rotations decreased at two weeks 
after drug administration. *p<0.01 CEPO-Fc, EPO-Fc vs PBS. F=7.27. 
 Fig. 7. Tyrosine hydroxylase immunostaining (TH) in the striatum. 
(A) Strong immunoreactivity found in intact striatum.  
(B) Severe destruction of TH-positive fibers in the PBS group. 
(C) Some preservation is seen in the EPO-Fc group.    
(D) Immunoreactivity is more clearly preserved in the CEPO-Fc group.                                         
(E) Graphic. Preservation of fibers was significantly better in both the EPO-Fc 
and the CEPO-Fc groups compared with the PBS group. Additionally, the CEPO-
Fc group exhibited significantly better preservation than the EPO-Fc group did. 
*p<0.05 EPO-Fc vs PBS, **p<0.01 CEPO-Fc vs EPO-Fc, ***p<0.0001 CEPO-Fc 
vs PBS. F=97.01.  
 
Fig. 8. Tyrosine hydroxylase immunostaining (TH) in the substantia nigra (SN) 
and VTA (ventral tegmental area). 
(A)TH-positive cells on SN intact side. 
(B) Almost complete absence of TH-positive cells in the PBS group. 
(C) Immunoreactivity is preserved in the EPO-Fc group.  
(D) Better preservation of TH-positive cells in the CEPO-Fc group.                        
(E) Graphic. Substantia Nigra. *p<0.05 EPO-Fc vs PBS; **p<0.05 CEPO-Fc vs 
PBS and F= 7.84. 
(F) Graphic. Ventral tegmental area. *p<0.01 EPO-Fc vs PBS; **p<0.0001 
CEPO-Fc vs PBS and F=95.99. 
TH-positive cells were significantly preserved in both the CEPO-Fc and EPO-Fc 
goups. Reversibly, there are severe loss of TH-positivel cells in PBS group. 
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